他汀类药物停药与 COVID-19 患者的治疗。
Statin withdrawal and treating COVID-19 patients.
机构信息
Sergy Haut, France.
出版信息
Pharmacol Res Perspect. 2021 Dec;9(6):e00861. doi: 10.1002/prp2.861.
Abstract
Most but not all observational studies of statin treatment of COVID-19 patients suggest that treatment improves outcomes. However, almost all of these studies fail to consider that withdrawing statins after hospital admission may have detrimental effects, a finding which cardiovascular investigators have known for 15-20 years. Continuing or starting statin treatment after hospital admission consistently improves cardiovascular outcomes. Similarly, inpatient statin treatment of COVID-19 improves survival. For this reason, observational studies of the effectiveness of outpatient-documented statin treatment of COVID-19 patients must consider the negative consequences of statin withdrawal after hospital admission.
摘要
大多数（但不是全部）关于他汀类药物治疗 COVID-19 患者的观察性研究表明，治疗可以改善结局。然而，几乎所有这些研究都没有考虑到住院后停用他汀类药物可能会产生不利影响，心血管研究人员在 15-20 年前就已经知道这一发现。在住院后继续或开始他汀类药物治疗始终可以改善心血管结局。同样，住院期间用他汀类药物治疗 COVID-19 可以提高生存率。因此，对于 COVID-19 患者门诊记录的他汀类药物治疗效果的观察性研究，必须考虑住院后停用他汀类药物的负面影响。
相似文献
1
Statin withdrawal and treating COVID-19 patients.他汀类药物停药与 COVID-19 患者的治疗。
Pharmacol Res Perspect. 2021 Dec;9(6):e00861. doi: 10.1002/prp2.861.
2
[Effect of delay statins withdrawal during admission in medical units].[住院期间延迟停用他汀类药物的影响]
Med Intensiva. 2010 May;34(4):268-72. doi: 10.1016/j.medin.2009.11.012. Epub 2010 Jan 22.
3
Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies.他汀类药物与 COVID-19 的临床结局：观察性研究的荟萃分析。
Diabetes Metab. 2021 Nov;47(6):101220. doi: 10.1016/j.diabet.2020.101220. Epub 2020 Dec 23.
4
Improved COVID-19 Outcomes following Statin Therapy: An Updated Systematic Review and Meta-analysis.他汀类药物治疗后 COVID-19 结局改善：更新的系统评价和荟萃分析。
Biomed Res Int. 2021 Sep 23;2021:1901772. doi: 10.1155/2021/1901772. eCollection 2021.
5
Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction.非ST段抬高型心肌梗死患者他汀类药物治疗的早期停药：心肌梗死国家注册研究
Arch Intern Med. 2004 Oct 25;164(19):2162-8. doi: 10.1001/archinte.164.19.2162.
6
Association between antecedent statin use and severe disease outcomes in COVID-19: A retrospective study with propensity score matching.他汀类药物使用与 COVID-19 严重疾病结局的关联：一项基于倾向评分匹配的回顾性研究。
J Clin Lipidol. 2021 May-Jun;15(3):451-459. doi: 10.1016/j.jacl.2021.03.002. Epub 2021 Mar 6.
7
Association of early statin initiation during COVID-19 admission with inpatient mortality at an academic health system in Illinois, March 2020 to September 2022: a target trial emulation using observational data.2020 年 3 月至 2022 年 9 月，伊利诺伊州一家学术医疗系统中 COVID-19 住院期间早期开始使用他汀类药物与住院死亡率的关联：使用观察性数据进行的目标试验模拟。
BMJ Open. 2024 Oct 1;14(10):e085547. doi: 10.1136/bmjopen-2024-085547.
8
Statin Use and In-hospital Mortality in Patients with COVID-19 and Coronary Heart Disease.他汀类药物在 COVID-19 合并冠心病患者中的应用与院内死亡率的关系。
Sci Rep. 2021 Dec 13;11(1):23874. doi: 10.1038/s41598-021-02534-2.
9
In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis.住院期间使用他汀类药物与降低 2019 年冠状病毒病（COVID-19）死亡率相关：系统评价和荟萃分析。
Pharmacol Rep. 2021 Jun;73(3):769-780. doi: 10.1007/s43440-021-00233-3. Epub 2021 Feb 20.
10
Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial.阿托伐他汀和阿司匹林作为 SARS-CoV-2 感染患者的辅助治疗：一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 30;21(1):902. doi: 10.1186/s13063-020-04840-y.
引用本文的文献
1
Potential role of geranylgeraniol in managing statin-associated muscle symptoms: a COVID-19 related perspective.香叶基香叶醇在管理他汀类药物相关肌肉症状中的潜在作用：COVID-19相关视角
Front Physiol. 2023 Nov 17;14:1246589. doi: 10.3389/fphys.2023.1246589. eCollection 2023.
2
Treating COVID-19: Targeting the Host Response, Not the Virus.治疗新冠病毒病：针对宿主反应，而非病毒。
Life (Basel). 2023 Mar 6;13(3):712. doi: 10.3390/life13030712.
3
A practical treatment for COVID-19 and the next pandemic.一种针对新冠病毒病及下一次大流行的实用治疗方法。
Pharmacol Res Perspect. 2022 Aug;10(4):e00988. doi: 10.1002/prp2.988.
4
Oral Drugs Against COVID-19.口服抗新冠病毒药物。
Dtsch Arztebl Int. 2022 Apr 15;119(15):263-269. doi: 10.3238/arztebl.m2022.0152.
5
Critical insights to COVID-19 disease and potential treatments using a systems analysis approach that integrates physiology, pharmacology, and clinical pharmacology.利用整合生理学、药理学和临床药理学的系统分析方法，对COVID-19疾病及潜在治疗方法的关键见解。
Pharmacol Res Perspect. 2022 Feb;10(1):e00918. doi: 10.1002/prp2.918.
6
Did our pharmacological strategy for COVID-19 fail?我们针对新冠病毒病的药理学策略失败了吗？
Pharmacol Res Perspect. 2021 Dec;9(6):e00866. doi: 10.1002/prp2.866.
本文引用的文献
1
Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs.比利时 COVID-19 患者在使用他汀类药物、ACE 抑制剂和/或 ARBs 治疗后的住院死亡率。
Hum Vaccin Immunother. 2021 Sep 2;17(9):2841-2850. doi: 10.1080/21645515.2021.1920271. Epub 2021 May 28.
2
Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry.他汀类药物预先治疗与 COVID-19 患者的改善结局相关：来自 SEMI-COVID-19 登记处的数据。
Drugs. 2021 Apr;81(6):685-695. doi: 10.1007/s40265-021-01498-x. Epub 2021 Mar 29.
3
Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19.COVID-19 住院患者中使用他汀类药物前史与死亡率降低的关联。
Nat Commun. 2021 Feb 26;12(1):1325. doi: 10.1038/s41467-021-21553-1.
4
Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis.评价在 ClinicalTrials.gov 上注册的心血管治疗 COVID-19 的临床试验特征：一项横断面分析。
Am Heart J. 2021 Feb;232:105-115. doi: 10.1016/j.ahj.2020.10.065. Epub 2020 Oct 26.
5
Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK.管理 COVID-19 患者和大流行期间的高脂血症：来自英国心脏协会的专家小组立场声明。
Atherosclerosis. 2020 Nov;313:126-136. doi: 10.1016/j.atherosclerosis.2020.09.008. Epub 2020 Sep 15.
6
A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID-19.在 COVID-19 中整合宿主治疗、药物重定位和损伤反应框架的药理学框架。
Br J Clin Pharmacol. 2021 Mar;87(3):875-885. doi: 10.1111/bcp.14551. Epub 2020 Nov 18.
7
COVID-19 is, in the end, an endothelial disease.COVID-19 归根结底是一种血管内皮疾病。
Eur Heart J. 2020 Sep 1;41(32):3038-3044. doi: 10.1093/eurheartj/ehaa623.
8
Beyond dexamethasone, emerging immuno-thrombotic therapies for COVID-19.COVID-19 的新型免疫血栓治疗方法：不止地塞米松。
Br J Clin Pharmacol. 2021 Mar;87(3):845-857. doi: 10.1111/bcp.14540. Epub 2020 Oct 14.
9
Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system.美国一家大型医疗系统中新冠病毒疾病（COVID-19）住院患者的早期临床和社会人口学经验。
EClinicalMedicine. 2020 Sep;26:100504. doi: 10.1016/j.eclinm.2020.100504. Epub 2020 Aug 19.
10
The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.血管紧张素受体阻滞剂（ARBs）、血管紧张素转换酶抑制剂（ACEis）和他汀类药物对养老院居民 COVID-19 感染临床结局的影响。
J Am Med Dir Assoc. 2020 Jul;21(7):909-914.e2. doi: 10.1016/j.jamda.2020.06.018. Epub 2020 Jun 15.
Zotero 插件